Hashimoto 橋本氏甲狀腺炎

COND-hashimoto

2

interventions reviewed

B

top tier

1

counter-evidence

B Preliminary 1

Published with Warning 🚨 高市場風險

D Counter-evidence 1

Insufficient Evidence ⚠️ 中度市場風險